Dr. Ira Shoulson, MD
- Neurology (Primary); board certifiedin 1980
Ira Shoulson, MD, is professor of neurology, pharmacology and human science, and Director of the Program for Regulatory Science and Medicine (PRSM) at Georgetown University as well as a member of the medical staff at MedStar Georgetown University Hospital and at MedStar Montgomery Medical Center. An internationally renowned expert in Huntington disease and Parkinson disease, Dr. Shoulson founded the Huntington Study Group in 1994 and the Parkinson Study Group in 1985 during his tenure as the Louis C. Lasagna Professor of Experimental Therapeutics and professor of neurology, pharmacology and medicine from 1990 to 2011, at the University of Rochester School of Medicine and Dentistry in Rochester, New York. These international academic consortia are devoted to research and development of treatments for Parkinson disease, Huntington disease and related neurodegenerative and neurogenetic disorders.
Dr. Shoulson was a key investigator in the US-Venezuela Collaborative Huntington Disease Project, which identified the gene responsible for this fatal hereditary disorder. He has served as principal investigator for key National Institutes of Health-sponsored trials on Huntington disease and Parkinson disease, and served in a leadership role for more than 35 other multi-center clinical research studies. He played an instrumental role in the development of 10 new drugs for neurological disorders, including seven for Parkinson disease, two for Huntington disease and one for attention deficit disorder. Dr. Shoulson was formerly a health policy fellow in the US Senate, a member of the National Institute of Neurological Disorders and Stroke Council, and president of the American Society for Experimental NeuroTherapeutics (ASENT).
Dr. Shoulson is currently principal investigator of the FDA-Georgetown University Collaborating Center of Excellence in Regulatory Science and Innovation (CERSI - FD004319), associate editor of JAMA Neurology and an elected member of the National Academy of Medicine of the National Academy of Sciences. He has authored more than 315 scientific reports.
- The Huntington Study Group PHAROS Investigators. Clinical-genetic associations in the prospective Huntington at risk observational study (PHAROS): implications for clinical trials. JAMA Neurol,
- The Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit. JAMA Neurol,
- Approaches and costs for sharing clinical research data (Viewpoint). JAMA. Published online February 20, 2014. https://jama.jamanetwork.com/article.aspx?articleid=1833396.
- for the Huntington Study Group COHORT Investigators. Natural History of Huntington Disease. JAMA Neurol,
- Parkinson Study Group SURE-PD Investigators. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized, placebo-controlled trial. JAMA Neurol, (Published online December 23, 2013).
- Residency Program: University of Rochester Medical Center (1976)
- Fellowship Program: National Institutes of Health (1975)
- Residency Program: Strong Memorial Hospital (1973)
- Internship Program: Strong Memorial Hospital (1972)
- Medical School: University of Rochester School of Medicine (1971)
- Medical School: University of Pennsylvania (1967)
- Founding Member, American Society Experimental NeuroTherapeutics (ASENT)
- Fellow, American College of Physicians
- Fellow, American Academy of Neurology
- Member, American Medical Association
- Member, Movement Disorder Society
- Member, American Neurological Association
- Member (elected), Institute of Medicine of the National Academies
- Honor Award, Huntington's Disease Foundation of America; National Huntington's Disease Association
- Michael J. Fox Foundation Executive Science Advisory Board and recipient of the Pritzker Prize
- Member, Institute of Medicine Social Security Administration Standing Committee, Social Security and Disability Issues, Principal Investigator
- FDA-Georgetown University Center of Excellence in Regulatory Science and Innovation (CERSI)